Catalog3 refs
Ovagen (EDL)
Healing & RecoveryResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
DNA
Overview
Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. It crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects via PEPT1/PEPT2 transporters.
Primary Uses
Reduces long-term liver fibrosis
Protects GI mucosal layer
Defense against antibiotic damage
Protection from environmental toxins
May protect against chemotherapy GI effects
Hepatoprotection through gene expression regulation
Addresses age-related liver changes
Supports GI tract function during aging
Protocol Reference
Dose
10-20 mg daily
Frequency
Daily for 10-20 days per cycle; 2-3 cycles yearly for maintenance
Half-life
Not established
Route
Oral capsules · Injectable
Evidence
Moderate Research
Research Models
Human
Also in Healing & Recovery